<table cellpadding="0pt" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<colgroup>
<col width="0%"></col>
<col width="18%"></col>
<col width="0%"></col>
<col width="82%"></col>
</colgroup>
<tbody>
<tr>
<td colspan="3" stylecode="Botrule Lrule Rrule Toprule" valign="top">
<content stylecode="bold">Drugs That Interfere with Hemostasis</content>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top">
<paragraph>• Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of </paragraph>
<paragraph>
<content>either drug </content>
</paragraph>
<paragraph>
<content>alone.</content>
</paragraph>
<paragraph>
<content></content>
<content>• </content>
<content>S</content>
<content>er</content>
<content>otonin</content>
</paragraph>
<paragraph>
<content></content>
<content>release by</content>
</paragraph>
<paragraph>
<content></content>
</paragraph>
<paragraph>
<content>platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone.</content>
</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top">Monitor patients with concomitant use of VOLTAREN<sup>®</sup> GEL with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#i4i_section_id_eb3f349f-a22c-4302-b87c-31f200a93236">5.11</linkhtml>)].</content>
</td>
</tr>
<tr>
<td colspan="3" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Aspirin</content>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top">Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#i4i_section_id_a4102012-8aad-42f2-ae2b-d063bfad095a">5.2</linkhtml>)].</content>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top">Concomitant use of VOLTAREN<sup>®</sup> GEL and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding <content stylecode="italics">[see Warnings and Precautions     (<linkhtml href="#i4i_section_id_eb3f349f-a22c-4302-b87c-31f200a93236">5.11</linkhtml>)].</content>
<paragraph></paragraph>
<paragraph>VOLTAREN<sup>®</sup> GEL is not a substitute for low dose aspirin for cardiovascular protection.</paragraph>
</td>
</tr>
<tr>
<td colspan="3" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers</content>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top">• NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme<paragraph></paragraph>
<paragraph>(ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta<content>blockers (including </content>propranolol).</paragraph>
<paragraph></paragraph>
<paragraph>
<content>• In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible </content>
</paragraph>
<paragraph>
<content>acute renal failure.</content>
</paragraph>
<paragraph></paragraph>
<paragraph>These effects are usually reversible.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Botrule Lrule Rrule Toprule" valign="top">• During concomitant use of VOLTAREN<sup>®</sup> GEL and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained.<paragraph></paragraph>
<paragraph>• During concomitant use of VOLTAREN<sup>®</sup> GEL and ACE-inhibitors or ARBs in patients who are elderly, volume-depleted, or have impaired renal function, monitor for signs of worsening renal function [see <content stylecode="italics">Warnings and Precautions (<linkhtml href="#i4i_section_id_f1ee462e-6625-4c06-891c-7be01a1f0393">5.6</linkhtml>)].</content>
</paragraph>•When these drugs are administered concomitantly, patients should be adequately hydrated. Assess renal function at the beginning of the concomitant treatment and periodically thereafter<content stylecode="italics">.</content>
</td>
</tr>
<tr>
<td colspan="3" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Diuretics</content>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td colspan="2" stylecode="Botrule Lrule Rrule Toprule" valign="top">Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis.</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td colspan="2" stylecode="Botrule Lrule Rrule Toprule" valign="top">During concomitant use of VOLTAREN<sup>®</sup> GEL with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects <content stylecode="italics">[</content>
<content stylecode="italics">see Warnings and Precautions (<linkhtml href="#i4i_section_id_f1ee462e-6625-4c06-891c-7be01a1f0393">5.6</linkhtml>)].</content>
</td>
</tr>
<tr>
<td colspan="4" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Digoxin</content>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="bottom">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td colspan="2" stylecode="Botrule Lrule Rrule Toprule" valign="top">The concomitant use of diclofenac with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td colspan="2" stylecode="Botrule Lrule Rrule Toprule" valign="top">During concomitant use of VOLTAREN<sup>®</sup> GEL and digoxin, monitor serum digoxin levels.</td>
</tr>
<tr>
<td colspan="4" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Lithium</content>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td colspan="2" stylecode="Botrule Lrule Rrule Toprule" valign="top">NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<paragraph>
<content stylecode="italics"> Intervention:</content>
</paragraph>
</td>
<td colspan="2" stylecode="Botrule Lrule Rrule Toprule" valign="top">During concomitant use of VOLTAREN<sup>®</sup> GEL and lithium, monitor patients for signs of lithium toxicity.</td>
</tr>
<tr>
<td colspan="4" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Methotrexate</content>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td colspan="2" stylecode="Botrule Lrule Rrule Toprule" valign="top">Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction).</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td colspan="2" stylecode="Botrule Lrule Rrule Toprule" valign="top">During concomitant use of VOLTAREN<sup>®</sup> GEL and methotrexate, monitor patients for methotrexate toxicity.</td>
</tr>
<tr>
<td colspan="4" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Cyclosporine</content>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="middle">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td colspan="2" stylecode="Botrule Lrule Rrule Toprule" valign="top">Concomitant use of VOLTAREN<sup>®</sup> GEL and cyclosporine may increase cyclosporine's nephrotoxicity.</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td colspan="2" stylecode="Botrule Lrule Rrule Toprule" valign="top">During concomitant use of VOLTAREN<sup>®</sup> GEL and cyclosporine, monitor patients for signs of worsening renal function.</td>
</tr>
<tr>
<td colspan="4" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">NSAIDs and Salicylates</content>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td colspan="2" stylecode="Botrule Lrule Rrule Toprule" valign="top">Concomitant use of diclofenac with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy <content stylecode="italics">[see Warnings and Precautions (<linkhtml href="#i4i_section_id_a4102012-8aad-42f2-ae2b-d063bfad095a">5.2</linkhtml>)].</content>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td colspan="2" stylecode="Botrule Lrule Rrule Toprule" valign="top">The concomitant use of diclofenac with other NSAIDs or salicylates is notrecommended.</td>
</tr>
<tr>
<td colspan="4" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Pemetrexed</content>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td colspan="2" stylecode="Botrule Lrule Rrule Toprule" valign="top">Concomitant use of VOLTAREN<sup>®</sup> GEL and pemetrexed may increase the risk of pemetrexed-associated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).</td>
</tr>
<tr>
<td colspan="2" stylecode="Botrule Lrule Rrule Toprule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td colspan="2" stylecode="Botrule Lrule Rrule Toprule" valign="top">During concomitant use of VOLTAREN<sup>®</sup> GEL and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and Gl toxicity.<paragraph></paragraph>
<paragraph>NSAIDs with short elimination half-lives (e.g., diclofenac, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed.</paragraph>
<paragraph></paragraph>
<paragraph>In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.</paragraph>
</td>
</tr>
</tbody>
</table>